title: In vitro stability of endogenous parathyroid hormone-related protein in blood and plasma.
abstract: We describe a systematic comparison of the effects of anticoagulants, protease inhibitors and conditions of sample handling on the in vitro stability of endogenous parathyroid hormone-related protein (PTHrP) in blood from patients with hypercalcaemia of malignancy (HM). When blood was separated within 15 min of collection, PTHrP1-86 levels measured by two-site immunoradiometric assay in serum and heparinized plasma were significantly lower than in ethylenediaminetetraacetic acid (EDTA) plasma (P < 0.02). PTHrP was unstable in blood kept at 20 degrees C for 4 h and inclusion of protease inhibitors reduced, but failed to abolish, this instability. In blood collected in the presence of EDTA, inclusion of leupeptin either alone or in combination with pepstatin and aprotinin increased the mean half-time of disappearance from 3.9 to 10.1 and 11.2 h, respectively (P < 0.05). In contrast, when blood containing EDTA was separated within 15 min, PTHrP was stable in plasma at 20 degrees C for at least 4 h. As a result of the instability of PTHrP1-86 immunoreactivity in whole blood at ambient temperatures we advise that for our immunoradiometric assay (IRMA) blood collected in EDTA should be separated within 15 min, and the plasma frozen until assay.
authors.affiliation: Department of Clinical Chemistry, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK.
authors.forename: A C
authors.initials: AC
authors.lastname: Hutchesson
authors.forename: S V
authors.initials: SV
authors.lastname: Hughes
authors.forename: S J
authors.initials: SJ
authors.lastname: Bowden
authors.forename: W A
authors.initials: WA
authors.lastname: Ratcliffe
mesh_terms: D000925:Anticoagulants / Q000494:pharmacology*; D007611:Aprotinin / Q000494:pharmacology; D001800:Blood Specimen Collection; D004492:Edetic Acid / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D006934:Hypercalcemia / Q000097:blood / Q000209:etiology; D015592:Immunoradiometric Assay; D066298:In Vitro Techniques; D007223:Infant; D007976:Leupeptins / Q000494:pharmacology; D009369:Neoplasms / Q000097:blood; D044162:Parathyroid Hormone-Related Protein; D010436:Pepstatins / Q000494:pharmacology; D010446:Peptide Fragments / Q000097:blood*; D010455:Peptides / Q000097:blood*; D011480:Protease Inhibitors / Q000494:pharmacology*; D013696:Temperature
chemical_list: D000925:Anticoagulants; D007976:Leupeptins; D044162:Parathyroid Hormone-Related Protein; D010436:Pepstatins; D010446:Peptide Fragments; D010455:Peptides; D011480:Protease Inhibitors; C068871:parathyroid hormone-related protein (1-86); C014195:Streptomyces pepsin inhibitor; D006493:Heparin; D007611:Aprotinin; D004492:Edetic Acid; C032854:leupeptin; C031375:pepstatin